Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798471 · ClinicalTrials.gov registry record · Phase 3
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT02798471 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 290 participants.
The verdict
NCT02798471, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.
Interventions
- DRUG Standard of Care
- DRUG Edoxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798471
The ClinicalTrials.gov registry entry for NCT02798471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT02798471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02798471 about?
NCT02798471 is a clinical study titled "Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)". This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of ...
What is the current status of trial NCT02798471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2017-03-27. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT02798471?
The interventions under investigation include: Standard of Care (DRUG), Edoxaban (DRUG).
Who is sponsoring clinical trial NCT02798471?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.